236 related articles for article (PubMed ID: 37344934)
1. Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences.
Kalkowska DA; Wassilak SGF; Wiesen E; Burns CC; Pallansch MA; Badizadegan K; Thompson KM
Risk Anal; 2024 Feb; 44(2):366-378. PubMed ID: 37344934
[TBL] [Abstract][Full Text] [Related]
2. Updated Characterization of Post-OPV Cessation Risks: Lessons from 2019 Serotype 2 Outbreaks and Implications for the Probability of OPV Restart.
Kalkowska DA; Pallansch MA; Cochi SL; Kovacs SD; Wassilak SGF; Thompson KM
Risk Anal; 2021 Feb; 41(2):320-328. PubMed ID: 32632925
[TBL] [Abstract][Full Text] [Related]
3. Looking back at prospective modeling of outbreak response strategies for managing global type 2 oral poliovirus vaccine (OPV2) cessation.
Thompson KM; Kalkowska DA; Badizadegan K
Front Public Health; 2023; 11():1098419. PubMed ID: 37033033
[TBL] [Abstract][Full Text] [Related]
4. Complexity of options related to restarting oral poliovirus vaccine (OPV) in national immunization programs after OPV cessation.
Kalkowska DA; Wassilak SG; Wiesen E; F Estivariz C; Burns CC; Badizadegan K; Thompson KM
Gates Open Res; 2023; 7():55. PubMed ID: 37547300
[No Abstract] [Full Text] [Related]
5. Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use.
Duintjer Tebbens RJ; Hampton LM; Thompson KM
BMC Infect Dis; 2018 Apr; 18(1):165. PubMed ID: 29631539
[TBL] [Abstract][Full Text] [Related]
6. Expected Implications of Globally Coordinated Cessation of Serotype 3 Oral Poliovirus Vaccine (OPV) Before Serotype 1 OPV.
Kalkowska DA; Thompson KM
Risk Anal; 2021 Feb; 41(2):312-319. PubMed ID: 32936466
[TBL] [Abstract][Full Text] [Related]
7. The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission.
Thompson KM; Duintjer Tebbens RJ
BMC Infect Dis; 2015 Sep; 15():376. PubMed ID: 26382234
[TBL] [Abstract][Full Text] [Related]
8. Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response.
Kalkowska DA; Pallansch MA; Wassilak SGF; Cochi SL; Thompson KM
Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A136-A141. PubMed ID: 33994237
[TBL] [Abstract][Full Text] [Related]
9. Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine.
Duintjer Tebbens RJ; Thompson KM
Expert Rev Vaccines; 2018 Aug; 17(8):739-751. PubMed ID: 30056767
[TBL] [Abstract][Full Text] [Related]
10. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation.
Duintjer Tebbens RJ; Hampton LM; Thompson KM
BMC Infect Dis; 2016 May; 16():231. PubMed ID: 27230071
[TBL] [Abstract][Full Text] [Related]
11. Implementing the Synchronized Global Switch from Trivalent to Bivalent Oral Polio Vaccines-Lessons Learned From the Global Perspective.
Ramirez Gonzalez A; Farrell M; Menning L; Garon J; Everts H; Hampton LM; Dolan SB; Shendale S; Wanyoike S; Veira CL; Châtellier GMD; Kurji F; Rubin J; Boualam L; Chang Blanc D; Patel M
J Infect Dis; 2017 Jul; 216(suppl_1):S183-S192. PubMed ID: 28838179
[TBL] [Abstract][Full Text] [Related]
12. Updated Characterization of Outbreak Response Strategies for 2019-2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain.
Kalkowska DA; Pallansch MA; Wilkinson A; Bandyopadhyay AS; Konopka-Anstadt JL; Burns CC; Oberste MS; Wassilak SGF; Badizadegan K; Thompson KM
Risk Anal; 2021 Feb; 41(2):329-348. PubMed ID: 33174263
[TBL] [Abstract][Full Text] [Related]
13. Analysis of population immunity to poliovirus following cessation of trivalent oral polio vaccine.
Voorman A; Lyons H; Bennette C; Kovacs S; Makam JK; F Vertefeuille J; Tallis G
Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A85-A92. PubMed ID: 35339308
[TBL] [Abstract][Full Text] [Related]
14. Health economic analysis of vaccine options for the polio eradication endgame: 2022-2036.
Thompson KM; Kalkowska DA; Badizadegan K
Expert Rev Vaccines; 2022 Nov; 21(11):1667-1674. PubMed ID: 36154436
[TBL] [Abstract][Full Text] [Related]
15. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use.
Duintjer Tebbens RJ; Hampton LM; Thompson KM
BMC Infect Dis; 2016 Jun; 16():237. PubMed ID: 27246198
[TBL] [Abstract][Full Text] [Related]
16. Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes.
Thompson KM; Duintjer Tebbens RJ
BMC Infect Dis; 2015 Sep; 15():374. PubMed ID: 26381878
[TBL] [Abstract][Full Text] [Related]
17. Eradicating polio: how the world's pediatricians can help stop this crippling illness forever.
Orenstein WA;
Pediatrics; 2015 Jan; 135(1):196-202. PubMed ID: 25548328
[TBL] [Abstract][Full Text] [Related]
18. Managing population immunity to reduce or eliminate the risks of circulation following the importation of polioviruses.
Thompson KM; Kalkowska DA; Duintjer Tebbens RJ
Vaccine; 2015 Mar; 33(13):1568-77. PubMed ID: 25701673
[TBL] [Abstract][Full Text] [Related]
19. Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs.
Duintjer Tebbens RJ; Thompson KM
BMC Infect Dis; 2015 Sep; 15():390. PubMed ID: 26404780
[TBL] [Abstract][Full Text] [Related]
20. Health Economic Analysis of Antiviral Drugs in the Global Polio Eradication Endgame.
Badizadegan K; Kalkowska DA; Thompson KM
Med Decis Making; 2023; 43(7-8):850-862. PubMed ID: 37577803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
